Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial

S.D. Anker, J. Butler, G. Filippatos, M.S. Khan, J.P. Ferreira, E. Bocchi, M. Bohm, H.P. Brunner-La Rocca, D.J. Choi, V. Chopra, E. Chuquiure, N. Giannetti, J.E. Gomez-Mesa, S. Janssens, J.L. Januzzi, J.R. Gonzalez-Juanatey, B. Merkely, S.J. Nicholls, S.V. Perrone, I.L. PinaP. Ponikowski, M. Senni, M.F. Seronde, D. Sim, J. Spinar, I. Squire, S. Taddei, H. Tsutsui, S. Verma, D. Vinereanu, J. Zhang, W. Jamal, S. Schnaidt, J.M. Schnee, M. Brueckmann, S.J. Pocock, F. Zannad, M. Packer, T.r.i.a.l. EMPEROR-Preserved, EMPEROR-Preserved Trial Committees and Investigators

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)2383-2392
Number of pages10
JournalEuropean journal of heart failure
Volume22
Issue number12
DOIs
Publication statusPublished - 1 Dec 2020

Keywords

  • Empagliflozin
  • Heart failure with preserved ejection fraction
  • Sodium&#8211
  • empagliflozin
  • glucose co&#8208
  • heart failure with preserved ejection fraction
  • sodium&#8211
  • transporter 2 inhibitors
  • SPIRONOLACTONE
  • OUTCOMES

Cite this